Comparison of autogenous and reactive type obsessive-compulsive disorders in terms of clinical characteristics: A meta-analysis study.

Obsessive-compulsive disorder (OCD) has been divided into two subgroups autogenous and reactive types, based on obsessive symptoms. To our knowledge, no meta-analysis study compares sociodemographic and clinical characteristics. Investigation of the differences between the two groups in terms of these basic characteristics may provide information about the accuracy of this classification. This is the first meta-analysis to examine gender, age at onset and some clinical differences between patients with autogenous and reactive OCD. Electronic bibliographic databases of Scopus and PubMed were searched up to March 2024. Random effect models were conducted for this meta-analysis. The analysis was carried out using the standardized mean difference as the outcome measure. Publication bias was evaluated using the Begg and Eggers funnel plot, and fail-safe N calculation using the Rosenthal approach. The current meta-analysis summarizes the data from primary studies comparing the gender rates, age at onset of OCD, severity of obsessive-compulsive symptoms, and severity of depression and anxiety symptoms between autogenous and reactive types of OCD. The results of this study showed that the rate of male gender was higher in the autogenous type OCD. In addition, increased severity of anxiety, and depression were associated with autogenous type OCD. There was no significant difference between groups regarding the severity of obsessive-compulsive symptoms. Age of OCD onset findings were insignificant, but excluding an outlier study suggested earlier onset in autogenous type OCD. These results support the distinction between autogenous and reactive type OCD.

Disruption of consciousness depends on insight in OCD and on positive symptoms in schizophrenia.

Disruption of conscious access contributes to the advent of psychotic symptoms in schizophrenia but could also explain lack of insight in other psychiatric disorders. In this study, we explored how insight and psychotic symptoms related to disruption of consciousness. We explored consciousness in patients with schizophrenia, patients with obsessive-compulsive disorder (OCD) with good vs. poor insight and matched controls. Participants underwent clinical assessments and performed a visual masking task allowing us to measure individual consciousness threshold. We used a principal component analysis to reduce symptom dimensionality and explored how consciousness measures related to symptomatology. We found that clinical dimensions could be well summarized by a restricted set of principal components which also correlated with the extent of consciousness disruption. More specifically, positive symptoms were associated with impaired conscious access in patients with schizophrenia whereas the level of insight delineated two subtypes of OCD patients, those with poor insight who had consciousness impairments similar to patients with schizophrenia, and those with good insight who resemble healthy controls. Our study provides new insights about consciousness disruption in psychiatric disorders, showing that it relates to positive symptoms in schizophrenia and with insight in OCD. In OCD, it revealed a distinct subgroup sharing neuropathological features with schizophrenia. Our findings refine the mapping between symptoms and cognition, paving the way for a better treatment selection.

Evaluating the Readability, Quality, and Reliability of Online Patient Education Materials on Spinal Cord Stimulation.

AIM: To obtain health-related information internet usage is rapidly increasing. However, there are concerns about the comprehensibility and reliability of internet-accessed health-related information. The aim of this research was to investigate the reliability, quality, and readability of patient education materials (PEMs) about spinal cord stimulation (SCS) on the internet. MATERIAL AND METHODS: A total of 114 websites suitable for the study were identified after a search on Google for the term "spinal cord stimulation." Gunning Fog (GFOG), Flesch-Kincaid Grade Level (FKGL), Flesch Reading Ease Score (FRES), and Simple Measure of Gobbledygook (SMOG) were used to determine the readability of sites. The credibility of the websites was assessed using the Journal of the American Medical Association (JAMA) score. Quality was assessed using the global quality score (GQS), the DISCERN score, and the Health on the Net Foundation code of conduct (HONcode). RESULTS: Evaluating the text sections, the mean SMOG and FKGL were 10.92 ± 1.61 and 11.62 ± 2.11 years, respectively, and the mean FRES and GFOG were 45.32 ± 10.71 and 14.62 ± 2.24 (both very difficult), respectively. Of all the websites, 10.5% were found to be of high quality, 13.2% were found to be of high reliability, and only 6.1% had a HONcode. A significant difference was found between the typologies of the websites and the reliability and quality scores (p < 0.05). CONCLUSION: The internet-based PEMs about SCS were found to have a readability level that exceeded the Grade 6 level recommended by the National Health Institute. However, the materials demonstrated low reliability and poor quality. It is advisable that websites addressing Spinal Cord Stimulation (SCS), a specific neuromodulation technique among various interventional strategies for chronic pain management, maintain readability standards in line with established indexes and provide content that is reliable and tailored to the general public's educational level.

Dose escalation in intrathecal baclofen therapy based on disease etiology: Can an a priori target dose be established? A ten-year follow-up study.

CONTEXT: Intrathecal baclofen (ITB) therapy is administered for severe, persistent spasticity that cannot be addressed by oral medication or other treatments. OBJECTIVE: We aimed to evaluate the target dose of ITB for severe, persistent spasticity based on disease etiology. METHODS: Data at baseline (discharge), 1, and 10 years from 102 patients who received ITB therapy between 1985 and 2011 were retrospectively collected. Patients were divided based on disease etiology (cerebral, spinal, or multiple sclerosis [MS]) to evaluate differences in dose requirements. A comprehensive literature review of the dose trends in ITB therapy was conducted. RESULTS: Patients with cerebral spasticity (n = 62) required the highest dose after discharge (102.66 ± 30.9 µg), 1 (402.29 ± 300.2 µg), and 10 years (578.74 ± 421.2 µg). Patients with spinal spasticity (n = 19) required an average of 82.89 ± 30.7 µg baclofen at discharge, 296.3 ± 224.6 µg after 1 year, and 522.63 ± 425.97 µg after 10 years. Patients with MS-related spasticity (n = 21) had a dose of 82.73 ± 39.3 µg baclofen at discharge, 226.95 ± 193.3 µg after 1 year, and 320.6 ± 261.4 µg after 10 years. The differences among the categories were significant after 1 and 10 years of therapy. CONCLUSIONS: The largest dose escalation occurs within the first year of ITB therapy. Our work provides a guideline for the initial dose setting during the inpatient stay after implantation and potentially expected dosage over the years thereafter, although this must always be adjusted individually.